FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281486345> ?p ?o ?g. }

• W4281486345 abstract "Abstract Background Viral suppression remains the most desired outcome in the management of patients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) and this can be achieved by an effective Antiretroviral Therapy (ART). However, some patients who achieve viral suppression may experience viral rebound with dire consequence. We evaluated viral suppression and rebound and their associated factors among adult patients on ART in Kumasi, Ghana. Methods This hospital-based retrospective study was conducted at the Komfo Anokye Teaching Hospital in Ghana. We reviewed the medical records of 720 HIV patients on ART. Statistical analyses were performed using SPSS Version 26.0 and GraphPad prism version 8.0. p < 0.05 was considered statistically significant. Results Proportions of patients with viral suppression and viral rebound were 76.1% and 21.0% respectively. Being diagnosed at WHO stage I [aOR = 11.40, 95% CI (3.54–36.74), p < 0.0001], having good adherence to ART [aOR = 5.09, 95% CI (2.67–9.73), p < 0.0001], taking Nevirapine-based regimen [aOR = 4.66, 95% CI (1.20–18.04), p = 0 .0260] and increasing duration of treatment ( p < 0.0001) were independently associated with higher odds of viral suppression. However, being diagnosed at WHO stage II (aOR = 7.39, 95% CI 2.67–20.51; p < 0.0001) and stage III (aOR = 8.62, 95% CI 3.16–23.50; p < 0.0001), having poor adherence (aOR = 175.48, 95% CI 44.30–695.07; p < 0.0001), recording baseline suppression value of 20–49 copies/mL (aOR = 6.43, 95% CI 2.72–15.17; p < 0.0001) and being treated with Zidovudine/Lamivudine/Efavirenz (aOR = 6.49, 95% CI 1.85–22.79; p = 0.004) and Zidovudine/Lamivudine/Nevirapine (aOR = 18.68, 95% CI 1.58–220.90; p = 0 .02) were independently associated with higher odds of viral rebound. Conclusion Approximately 76% viral suppression rate among HIV patients on ART in Kumasi falls below the WHO 95% target by the year 2030. Choice of ART combination, drug adherence, WHO clinical staging and baseline viral load are factors associated with suppression or rebound. These clinical characteristics of HIV patients must be monitored concurrently with the viral load." @default.
• W4281486345 created "2022-05-26" @default.
• W4281486345 creator A5010171889 @default.
• W4281486345 creator A5012589194 @default.
• W4281486345 creator A5021938754 @default.
• W4281486345 creator A5024906207 @default.
• W4281486345 creator A5043089114 @default.
• W4281486345 creator A5053730427 @default.
• W4281486345 creator A5059193976 @default.
• W4281486345 creator A5063987665 @default.
• W4281486345 creator A5065463964 @default.
• W4281486345 creator A5068350283 @default.
• W4281486345 creator A5071035307 @default.
• W4281486345 creator A5089458910 @default.
• W4281486345 date "2022-05-25" @default.
• W4281486345 modified "2023-10-02" @default.
• W4281486345 title "Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana" @default.
• W4281486345 cites W1057084972 @default.
• W4281486345 cites W154148415 @default.
• W4281486345 cites W1990584242 @default.
• W4281486345 cites W2052940672 @default.
• W4281486345 cites W2057394385 @default.
• W4281486345 cites W2088056388 @default.
• W4281486345 cites W2105750719 @default.
• W4281486345 cites W2113643689 @default.
• W4281486345 cites W2126952925 @default.
• W4281486345 cites W2128886090 @default.
• W4281486345 cites W2154658760 @default.
• W4281486345 cites W2162299988 @default.
• W4281486345 cites W2171927211 @default.
• W4281486345 cites W2346261512 @default.
• W4281486345 cites W2464127715 @default.
• W4281486345 cites W2491572170 @default.
• W4281486345 cites W2551459315 @default.
• W4281486345 cites W2564247579 @default.
• W4281486345 cites W2568194123 @default.
• W4281486345 cites W2610466423 @default.
• W4281486345 cites W2611773854 @default.
• W4281486345 cites W2748983855 @default.
• W4281486345 cites W2807088745 @default.
• W4281486345 cites W2981540939 @default.
• W4281486345 cites W2984296716 @default.
• W4281486345 cites W3005784155 @default.
• W4281486345 cites W3008373556 @default.
• W4281486345 cites W3016297638 @default.
• W4281486345 cites W3033543278 @default.
• W4281486345 cites W3107318896 @default.
• W4281486345 cites W3187142408 @default.
• W4281486345 cites W4243230195 @default.
• W4281486345 doi "https://doi.org/10.1186/s12981-022-00447-2" @default.
• W4281486345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35614510" @default.
• W4281486345 hasPublicationYear "2022" @default.
• W4281486345 type Work @default.
• W4281486345 citedByCount "4" @default.
• W4281486345 countsByYear W42814863452022 @default.
• W4281486345 countsByYear W42814863452023 @default.
• W4281486345 crossrefType "journal-article" @default.
• W4281486345 hasAuthorship W4281486345A5010171889 @default.
• W4281486345 hasAuthorship W4281486345A5012589194 @default.
• W4281486345 hasAuthorship W4281486345A5021938754 @default.
• W4281486345 hasAuthorship W4281486345A5024906207 @default.
• W4281486345 hasAuthorship W4281486345A5043089114 @default.
• W4281486345 hasAuthorship W4281486345A5053730427 @default.
• W4281486345 hasAuthorship W4281486345A5059193976 @default.
• W4281486345 hasAuthorship W4281486345A5063987665 @default.
• W4281486345 hasAuthorship W4281486345A5065463964 @default.
• W4281486345 hasAuthorship W4281486345A5068350283 @default.
• W4281486345 hasAuthorship W4281486345A5071035307 @default.
• W4281486345 hasAuthorship W4281486345A5089458910 @default.
• W4281486345 hasBestOaLocation W42814863451 @default.
• W4281486345 hasConcept C126322002 @default.
• W4281486345 hasConcept C142462285 @default.
• W4281486345 hasConcept C146357865 @default.
• W4281486345 hasConcept C151730666 @default.
• W4281486345 hasConcept C156957248 @default.
• W4281486345 hasConcept C167135981 @default.
• W4281486345 hasConcept C195910791 @default.
• W4281486345 hasConcept C203014093 @default.
• W4281486345 hasConcept C2779130552 @default.
• W4281486345 hasConcept C2781413609 @default.
• W4281486345 hasConcept C2993143319 @default.
• W4281486345 hasConcept C3013748606 @default.
• W4281486345 hasConcept C71924100 @default.
• W4281486345 hasConcept C86803240 @default.
• W4281486345 hasConcept C90924648 @default.
• W4281486345 hasConceptScore W4281486345C126322002 @default.
• W4281486345 hasConceptScore W4281486345C142462285 @default.
• W4281486345 hasConceptScore W4281486345C146357865 @default.
• W4281486345 hasConceptScore W4281486345C151730666 @default.
• W4281486345 hasConceptScore W4281486345C156957248 @default.
• W4281486345 hasConceptScore W4281486345C167135981 @default.
• W4281486345 hasConceptScore W4281486345C195910791 @default.
• W4281486345 hasConceptScore W4281486345C203014093 @default.
• W4281486345 hasConceptScore W4281486345C2779130552 @default.
• W4281486345 hasConceptScore W4281486345C2781413609 @default.
• W4281486345 hasConceptScore W4281486345C2993143319 @default.
• W4281486345 hasConceptScore W4281486345C3013748606 @default.
• W4281486345 hasConceptScore W4281486345C71924100 @default.
• W4281486345 hasConceptScore W4281486345C86803240 @default.
• W4281486345 hasConceptScore W4281486345C90924648 @default.

• next